Article Text

Download PDFPDF
Mesenchymal stem cell therapy of Crohn's disease: are the far-away hills getting closer?
  1. Julián Panés1,2,3,
  2. Daniel Benitez-Ribas2,
  3. Azucena Salas2,3
  1. 1Department of Gastroenterology, Hospital Clínic Barcelona, Barcelona, Spain
  2. 2Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, Barcelona, Spain
  3. 3Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
  1. Correspondence to Dr Julián Panés, Department of Gastroenterology, Hospital Clínic of Barcelona, Villarroel 170, Barcelona 08036, Spain; jpanes{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Persistence of unmet therapeutic needs in patients with Crohn's disease with luminal or perianal refractory disease has fostered the interest in innovative cellular immunoregulatory and regenerative medicines. Apart from autologous haematopoietic stem cell transplant, in which efficacy has been suggested in small series of patients and is now being evaluated in controlled trials, various groups have undertaken initiatives to determine the potential of mesenchymal stromal cell (MSC)-based therapy in Crohn's disease.

Bone marrow MSCs were first identified by Friedenstein, who described an adherent fibroblast-like population able to differentiate into bone. He referred to these cells as osteogenic precursor cells.1 Subsequent studies demonstrated that these cells have the ability to differentiate into various other mesodermal cell lineages, including chondrocytes, tenocytes and myoblasts. Based on this multilineage differentiation capacity, the term ‘mesenchymal stem cells’ was introduced.2 Although MSCs at a population level fulfil stem-cell criteria (ie, self-renewal and the capacity for multi-lineage differentiation), it remains questionable whether the qualification ‘stem cell’ is legitimate for MSCs at the single-cell level. It was therefore recently proposed that the term ‘multipotent mesenchymal stromal cells’ (with the abbreviation MSCs) should be used to describe fibroblast-like plastic-adherent cells.3

Although, originally, MSCs were isolated from bone marrow, similar populations have been isolated from other tissues, including adipose tissue, placenta, amniotic fluid and fetal tissues such as fetal lung and blood.2 To date, the isolation of MSCs still relies on their adherence to plastic, resulting in a heterogeneous population of adherent cells. No specific marker or combination of markers has been identified that specifically defines MSCs. Phenotypically, ex vivo expanded MSCs express a number of non-specific markers, including CD105 (SH2 or endoglin), CD73 (SH3 or SH4), CD90, CD166, CD44, and CD29, and are devoid …

View Full Text


  • Linked articles 221127.

  • Funding This work was supported, in part, by grant 2009/07272 from Ministerio de Ciencia e Innovación from Spain.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles